Investors have certainly endured some nausea-inducing rides in biotech.
Investors have certainly endured some nausea-inducing rides in biotech. The scrupulously objective Hulbert Financial Digest tracks MTSL's performance. Five years ago, as two separate scientific teams announced that they had finished decoding the human genome, investors glommed onto tiny Human Genome Sciences Inc. The days when investors rushed into the sector based on one company's successful clinical trial are long gone. Robert LenznerSteven Drobny reveals insights from the hedge fund all-stars.
When companies do deliver the goods, the market can still respond swiftly. In fact, we refuse to accept any compensation from the companies we cover.